학술논문

Osimertinib vs. erlotinib plus bevacizumab or ramucirumab for EGFR mutated NSCLC; a retrospective study from LC-SCRUM-Asia
Document Type
Journal
Source
ANNALS OF ONCOLOGY; JUL 2022, 33 pS510-pS510, 1p. Supplement: 6
Subject
Language
English
ISSN
15698041